DHPA

  • Home
  • About Us
    • Leadership
      • Executive Committee
      • Board Members
    • DHPA Members
    • Contact Us
    • Join Us
  • Advocacy
    • Patient Access to Independent GI Care
      • Colorectal Cancer Screening
    • Diversity Equity and Inclusion
    • Modernizing the Stark Law
    • Saving the IOASE
    • Pathology Services Utilization
  • Resources
    • CRC Screening
    • Independent GI Careers
    • Research
    • Fact Sheets
    • Letters to Policymakers
    • Leadership Series
  • Newsroom
    • Press Releases
    • DHPA in the News
    • GI News Round Up
  • Take Action

January 18, 2018

DHPA Urges Congress to Reverse CMS Policy Linking MIPS Adjustments to Part B Drug Costs

DHPA joined more than 100 of the nation’s leading patient and provider organizations in urging Congressional leaders to reverse a new Centers for Medicare & Medicaid Services (CMS) policy that will create enormous financial uncertainty for specialty providers and jeopardize patient access to vital Part B drug therapies.

CMS included the policy change in its CY 2018 Quality Payment Program Final Rule despite opposition from healthcare advocates and Congressional leaders.

In letters sent to leaders of the U.S. Senate Finance Committee and U.S. House Ways & Means and U.S. House Energy & Commerce Committees, the coalition writes that the recent CMS decision to adjust providers’ reimbursements for Part B drug costs based on their performance in the Merit-Based Incentive Payment System (MIPS) creates enormous financial risk for specialties that administer Part B drugs and will lead to significant access issues for patients who rely on these therapies.

“This application of the adjustment is not in line with the goals of MACRA, is a significant departure from current policy and would disproportionally affect certain specialties,” the groups write in the letters. “We believe this policy could make it more difficult for physicians, particularly those in rural settings, to administer Part B medications in their communities, creating a dire patient access issue.”

Click here to read the full U.S. House letter.

Click here to read the fill U.S. Senate letter.

Filed Under: Uncategorized

Member Spotlight

Allied Digestive Health is a gastroenterology and hepatology practice with more than 50 locations throughout New Jersey and New York, specializing in colon cancer screening, and the treatment of Celiac Disease, GERD, and IBD.

Learn more at:
www.allieddigestivehealth.com

Become a Member

    Is your practice interested in promoting and preserving accessible, high quality and cost-efficient care in the independent GI medical setting? Contact us today about joining DHPA.

    Recent News

    • DHPA Supports the Protecting Patient Access to Cancer and Complex Therapies Act

    • DHPA Supports Guidelines that Recommend Colorectal Cancer Screening Starting at Age 45

    • Video: Establishing a Formal Mentorship Program in an Independent GI Practice

    • UnitedHealthcare’s Advance Notification Policy: Paperwork Over Patient Care

    • Statement on UnitedHealthcare’s Advance Notification Policy for Gastroenterology Services

    • Colorectal Cancer: Am I at Risk? Spanish Translation (Video)

    • The Value of Colonoscopy: The Gold Standard in Colorectal Cancer Screening (Video)

    • Colorectal Cancer: Am I at Risk? (Video)

    • The Value of Colonoscopy (Infographic)

    Digestive Health Physicians Association, Inc.
    10770 Columbia Pike, Suite 400
    Silver Spring, Maryland, 20901
    © 2020 DHPA

    Follow @DHPAnews
    Tweets by DHPAnews

    Copyright © 2023 · Executive Pro Theme on Genesis Framework · WordPress · Log in